Stay up to date with our newsletter

Get in touch!

What can we do to help?

I would like to:

Lets start the conversation!

Sign up to our newsletter

View open positions on our Careers page,
or connect with us on Linkedin Twitter Facebook Youtube

Thank you!
We will be in touch shortly.

2019.12.18

Jay Stella joins Sai Life Sciences as Chief Business Officer

Jay Stella

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the appointment of Jay Stella as Chief Business Officer, to lead the overall business development and program management for the company. Jay will be based out of Cambridge, Massachusetts, United States and report to the CEO & Managing Director, Krishna Kanumuri.

Jay Stella brings over 25 years of leadership in the pharmaceutical and medical devices industries with extensive experience across R&D, Manufacturing, Business Development, Finance, and Post-M&A Integrations. He held positions of increasing responsibility at Millennium Pharmaceuticals and Takeda Pharmaceuticals for 15 years, across strategy & operations, business development, and integrations & divestitures, while also gaining significant experience in the Japanese cultural and business environment. Earlier, he worked for medium sized biotech companies, Biogen and Genetics Institute, where he held various financial and operational roles. Prior to the pharmaceutical industry, Jay worked in technical operations, manufacturing, planning, and strategic sourcing roles in the medical device industry. Jay received his MBA from Boston University and his Baccalaureate degree from the University of Vermont in Spanish with minors in Chemistry and Biology.

Making the announcement, Krishna Kanumuri said, “Inducting top-notch global leadership and scientific talent is a key priority as part of our transformative effort, Sai Nxt. We are delighted to have Jay on board in this exciting phase.”

Sai Nxt is an organization-wide initiative aimed at transforming the company into a new generation CDMO. With investments of over US $ 150 million between 2019 and 2023, the transformation focus is on three key areas – People & culture, Processes & automation, Infrastructure & scientific capabilities.

Commenting on his appointment, Jay Stella said, “I am very excited to join Sai Life Sciences at this pivotal point in the company’s journey. Sai’s vision to support global innovators bring 25 new medicines to life by 2025 is an inspiring one, and I look forward to playing a part in achieving it.”

News

2020.11.20

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), announced the opening of its representative office in Tokyo, Japan. The new office will serve as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region. A seasoned industry […]
Read more

2020.10.26

Biology, DMPKT & Vivarium

Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus

Commences construction of new 75,000 sq. ft. facility in Hyderabad Augmenting India team to 170 biologists Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility […]
Read more

2020.10.23

Green Chemistry Awards

Sai Life Sciences introduces Green Chemistry Awards

With the purpose of celebrating and recognizing teams and projects that demonstrate notable work in Green Chemistry, Sai Life Sciences instituted the ‘Green Chemistry Awards’ earlier this year. Using an internally developed computational model, projects were assessed on their ‘Greenness Index’ that is a composite of several attributes across atom & mass efficiency, e-factor, water […]
Read more

2020.10.23

ICH-M7 Services

Comprehensive ICH-M7 assessments for starting materials, intermediates, and final API

Sai Life Sciences offers comprehensive ICH-M7 services to help assess the potential risks of our customers’ starting materials, intermediates, and final API for mutagenicity assessment. As mandated in the ICH M7 guidelines, pharmaceutical companies are now required to assess, identify, and categorize their starting materials, intermediates and final API routes of synthesis and resulting impurities […]
Read more

2020.09.10

Discovery Biology Laboratory in Cambridge, MA, USA

Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA

Sai Life Sciences today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA. Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities include the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and […]
Read more